Video

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

Author(s):

Patrick Hwu, MD

In Partnership With:

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Patrick Hwu, MD, president, CEO, Moffitt Cancer Center, discusses the uptake of cellular therapy in the treatment of patients with cancer.

The integration of cellular therapy has transformed the treatment paradigms of many oncologic malignancies. Additional research regarding cellular therapy is necessary to continue the growth of their therapeutic modality. Moffitt Cancer Center was a leader in developing and utilizing the CD19-directed CAR T-cell therapy, says Hwu.

Beyond cellular therapy, expanding the use of targeted therapy, as well as cancer-prevention strategies are long-term goals of Moffitt Cancer Center and the oncology field in general, concludes Hwu.

Related Videos
Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University
Ewa Kalinka, MD, PhD
Rohan Garje, MD
Aparna Parikh, MD, medical oncologist, Massachusetts General Hospital
Tycel J. Phillips, MD, MPH
Dr Baljevic on Selinexor Plus Pomalidomide/Dexamethasone in R/R Myeloma
Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS
Naval G. Daver, MD,
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Phillip Phillip, MD
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

FDA
January 16th 2025

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Erica L. Mayer, MD, MPH
January 13th 2025

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

Dasom (Caroline) Lee, MD
January 6th 2025

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL